High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma (NCT06480396) | Clinical Trial Compass
Not Yet RecruitingPhase 3
High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
Italy, United Kingdom584 participantsStarted 2024-11
Plain-language summary
The SARveillance trial is an efficient, pragmatic, multi-centre, international, stratified, partially-randomised, patient-preference trial within a registry of high versus lower intensity radiological surveillance following primary resection of retroperitoneal, abdominal and pelvic soft tissue sarcoma. The trial design is stratified by sarcoma tumour grade (high/intermediate grade and low grade).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients (greater than 18 years)
* Primary resection
* Histologically confirmed retroperitoneal, abdominal or pelvic soft tissue sarcoma
* R0/R1 resection
* Eligible whether or not the participant undergoes neoadjuvant treatment
Exclusion Criteria:
* Metastatic disease at time of randomisation
* Recurrent, metastatic or residual disease identified on baseline CT imaging (3-4 months post primary resection)
* Reoperation for recurrent soft tissue sarcoma
* Re-resection following previous inadequate surgery
* R2 resection
* Patients receiving adjuvant therapy that will delay, interrupt or render radiological surveillance unpredictable
* Uterine sarcomas, gastrointestinal stromal tumour (GIST), fibromatosis, epithelial tumours, multifocal disease, sarcomas of bony origin
* Patient declined to consent to data sharing with RESAR (unless in a centre contributing via pre-planned IPDMA)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Emotional Functioning
Timeframe: 5 years
Trial details
NCT IDNCT06480396
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano